Immunotherapy-based regimens show promise in gastric cancer treatment

A meta-analysis of high-quality trials shows immunotherapy-based neoadjuvant regimens, particularly combining immunotherapy with chemotherapy and targeted therapy, significantly improve pathological complete response (PCR) rates and overall survival in locally advanced gastric cancer. The neoadjuvant immunotherapy plus chemotherapy (NICT) and NICT plus targeted therapy (NICTT) groups outperformed traditional chemotherapy, although the NICTT group faced increased severe treatment-related adverse events. The study highlights that certain tumor characteristics may enhance responsiveness to these novel regimens.